Investor Overview

Investor Overview

Corporate Profile
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in regulating cellular metabolism and inflammation. Our two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target important transcription factors, called Nrf2 and NF-κB, to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. Read More >>
RETA (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$21.57
Change (%) Stock is Down 1 (0.00%)
Volume103,630
Data as of 12/08/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock chart for: RETA.O.  Currently trading at $21.57 with a 52 week high of $41.60 and a 52 week low of $11.03.
Data provided by Nasdaq. Minimum 15 minutes delayed.


Investor Contact
Lee M. Stern, CFA
The Trout Group
Phone: (646) 378-2922
E-mail: IR@reatapharma.com